The GOLD Initiative 2011: A Change of Paradigm?;Iniciativa GOLD 2011. ¿Cambio de paradigma?

Archivos de Bronconeumologia

Volumn 48, Issue 8, 2012, Pages 286-289

  Rodríguez Roisin, Roberto ^a   Agustí, Alvar ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Junta Directiva de GOLD   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); Comorbidities; Multidimensional evaluation; Quality of life; Spirometric classification; Stable COPD treatment; Symptoms

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; DIAGNOSTIC TEST; GLOBAL STRATEGY FOR THE DIAGNOSIS MANAGEMENT AND PREVENTION OF COPD; PUBLICATION; PUBLISHING; SHORT SURVEY; TREATMENT INDICATION; WEB BROWSER;

EID: 84863865329     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2012.06.002     Document Type: Short Survey

References (14)

1. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
2. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Update 2011 [consultado 1 Feb 2012]. Disponible en: http://www%20goldcopd%20org/.
3. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
4. Soler-Cataluna J.J., Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious. COPD 2010, 7:276-284.
5. Mahler D.A., Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest 1988, 93:580-586.
6. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009, 34:648-654.
7. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001, 56:880-887.
8. Mannino D.M., Buist A.S., Vollmer W.M. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function. Thorax 2007, 62:237-241.
9. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
10. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
11. Bakke P.S., Ronmark E., Eagan T., Pistelli F., Annesi-Maesano I., Maly M., et al. Recommendations for epidemiological studies on COPD. Eur Respir J 2011, 38:1261-1277.
12. Rodriguez-Roisin R. Arguments against inhaled glucocorticoids in COPD by phenotype instead of by severity. Arch Bronconeumol 2011, 47:269-270.
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S.
14. Agusti A., Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:507-513.